论文部分内容阅读
[目的]探讨Ki-67在宫颈鳞癌新辅助化疗(NACT)前后表达的意义。[方法]在新辅助化疗前后用免疫组化方法检测32例宫颈鳞癌组织Ki-67的表达。[结果]化疗前后Ki-67阳性表达率分别为96.9%(31/32)和84.4%(26/32),差异有统计学意义(P=0.045);不同年龄段,临床期别和病理分级患者,化疗前后Ki-67阳性表达率无统计学差异。新辅助化疗总有效率为100%(32/32),完全缓解率40.6%(13/32),部分缓解率59.4%(19/32)。化疗前Ki-67的表达程度不同,完全缓解率明显不同,Ki-67(-)和(+)组CR率为1/9,与(++)和(+++)组的CR率52.2%(12/23)比较有统计学差异(P=0.033)。[结论]宫颈鳞癌新辅助化疗前Ki-67阳性表达强度和化疗后阳性表达率下降程度可能与化疗敏感性密切相关,但Ki-67是否能作为判断宫颈鳞癌新辅助化疗敏感性的指标尚不能确定。
[Objective] To investigate the significance of Ki-67 expression in cervical squamous cell carcinoma before and after neoadjuvant chemotherapy (NACT). [Method] The expression of Ki-67 in 32 cases of cervical squamous cell carcinoma was detected by immunohistochemistry before and after neoadjuvant chemotherapy. [Results] The positive rates of Ki-67 before and after chemotherapy were 96.9% (31/32) and 84.4% (26/32), respectively, with statistical significance (P = 0.045). The positive rates of Ki-67 in different age groups, clinical stage and pathological grade Patients, Ki-67 positive expression rate before and after chemotherapy was no significant difference. The total effective rate of neoadjuvant chemotherapy was 100% (32/32), complete remission rate was 40.6% (13/32), and partial remission rate was 59.4% (19/32). The expression of Ki-67 was different before chemotherapy, and the complete remission rate was significantly different. The CR rate was 1/9 in Ki-67 (-) and (+) groups, and 52.2 % (12/23) was statistically significant (P = 0.033). [Conclusion] The positive expression of Ki-67 in cervical squamous cell carcinoma before neoadjuvant chemotherapy may be related to the sensitivity of chemosensitivity. However, whether Ki-67 can be used as an index to judge the neoadjuvant chemosensitivity of cervical squamous cell carcinoma Still not sure.